- Home
- TSI vs ENLV Comparison
TSI vs ENLV Comparison
Compare TSI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | ENLV |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.7M | 258.7M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TSI | ENLV |
|---|---|---|
| Price | $4.51 | $0.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 255.8K | ★ 552.0K |
| Earning Date | 01-01-0001 | 03-25-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.43 | $0.66 |
| 52 Week High | $5.06 | $2.10 |
Technical Indicators
Market Signals| Indicator | TSI | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 41.79 |
| Support Level | N/A | $0.81 |
| Resistance Level | $4.95 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 27.11 | 18.11 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.